SUTRO BIOPHARMA, INC.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
STRO$9.62+4.6%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(In thousands, except share and per share data)
| June 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $64,025 | $190,304 |
| Marketable securities | 141,106 | 126,591 |
| Accounts receivable | 7,999 | 8,616 |
| Prepaid expenses and other current assets | 18,500 | 17,799 |
| Total current assets | 231,630 | 343,310 |
| Property and equipment, net | 14,981 | 18,190 |
| Operating lease right-of-use assets | 14,836 | 17,677 |
| Other non-current assets | 50 | 7,172 |
| Restricted cash | 858 | 858 |
| Total assets | $262,355 | $387,207 |
| Liabilities and Stockholders’ (Deficit) Equity | ||
| Current liabilities: | ||
| Accounts payable | $4,308 | $10,475 |
| Accrued compensation | 11,764 | 12,905 |
| Deferred revenue - current | 11,964 | 69,783 |
| Operating lease liability - current | 8,057 | 7,480 |
| Accrued expenses and other current liabilities | 38,153 | 31,250 |
| Total current liabilities | 74,246 | 131,893 |
| Deferred revenue - non-current | 6,906 | 12,536 |
| Operating lease liability - non-current | 11,536 | 15,674 |
| Deferred royalty obligation related to the sale of future royalties | 200,084 | 180,809 |
| Other non-current liabilities | 1,694 | 1,694 |
| Total liabilities | 294,466 | 342,606 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ (deficit) equity: | ||
| Preferred stock, $0.001 par value — 10,000,000 shares authorized as of June 30, 2025 and December 31, 2024; no shares issued and outstanding as of June 30, 2025 and December 31, 2024 | — | — |
| Common stock, $0.001 par value — 300,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 84,720,047 and 82,526,430 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | 85 | 83 |
| Additional paid-in-capital | 842,153 | 831,348 |
| Accumulated other comprehensive (loss) income | (13) | 39 |
| Accumulated deficit | (874,336) | (786,869) |
| Total stockholders’ (deficit) equity | (32,111) | 44,601 |
| Total Liabilities and Stockholders’ (Deficit) Equity | $262,355 | $387,207 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.